CR20140466A - Anticuerpos anti-baff-antil-il-17 biespecíficos - Google Patents
Anticuerpos anti-baff-antil-il-17 biespecíficosInfo
- Publication number
- CR20140466A CR20140466A CR20140466A CR20140466A CR20140466A CR 20140466 A CR20140466 A CR 20140466A CR 20140466 A CR20140466 A CR 20140466A CR 20140466 A CR20140466 A CR 20140466A CR 20140466 A CR20140466 A CR 20140466A
- Authority
- CR
- Costa Rica
- Prior art keywords
- baff
- biespectives
- antil
- interleukin
- high affinity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261636302P | 2012-04-20 | 2012-04-20 | |
| US201361768747P | 2013-02-25 | 2013-02-25 | |
| PCT/US2013/036677 WO2013158577A1 (en) | 2012-04-20 | 2013-04-16 | Anti-baff-anti-il-17 bispecific antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20140466A true CR20140466A (es) | 2014-11-13 |
Family
ID=48539373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20140466A CR20140466A (es) | 2012-04-20 | 2014-10-06 | Anticuerpos anti-baff-antil-il-17 biespecíficos |
Country Status (39)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9932403B2 (en) | 2010-05-20 | 2018-04-03 | Ablynx Nv | Biological materials related to HER3 |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| AR090626A1 (es) * | 2012-04-20 | 2014-11-26 | Lilly Co Eli | Anticuerpos anti-baff-anti-il-17 biespecificos |
| TW201444867A (zh) * | 2013-03-08 | 2014-12-01 | Lilly Co Eli | 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體 |
| PH12022550138A1 (en) | 2013-03-13 | 2023-03-06 | Amgen Inc | Proteins specific for baff and b7rp1 and uses thereof |
| US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
| MY183188A (en) | 2013-11-19 | 2021-02-18 | Regeneron Pharma | Non-human animals having a humanized b-cell activating factor gene |
| CA2934965A1 (en) | 2014-01-31 | 2016-03-17 | Boehringer Ingelheim International Gmbh | Novel anti-baff antibodies |
| AR102417A1 (es) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
| PE20180774A1 (es) * | 2015-07-23 | 2018-05-07 | Boehringer Ingelheim Int | Compuesto que se dirige a il-23a y al factor de activacion de linfocitos b (baff) y usos de estos |
| CN105061596B (zh) * | 2015-08-05 | 2019-01-29 | 江苏诺迈博生物医药科技有限公司 | 人b淋巴细胞刺激因子的单克隆抗体及其应用 |
| WO2019136311A2 (en) * | 2018-01-05 | 2019-07-11 | Biograph 55, Inc. | Compositions and methods for cancer immunotherapy |
| CN109053895B (zh) | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| CN117529506A (zh) * | 2021-06-11 | 2024-02-06 | 海南先声药业有限公司 | 抗人il-17抗体和taci的双功能融合蛋白分子 |
| CN121039167A (zh) * | 2022-12-28 | 2025-11-28 | 苏州创胜医药集团有限公司 | 包含抗baff抗体的双特异性结合蛋白及其用途 |
| TW202440636A (zh) | 2023-03-21 | 2024-10-16 | 美商傳記５５有限公司 | Ｃｄ１９／ｃｄ３８多特異性抗體 |
| AU2024386429A1 (en) | 2023-11-22 | 2026-05-21 | Mabylon Ag | Multispecific anti-allergen antibodies and uses thereof |
| AU2023474055A1 (en) | 2023-11-23 | 2026-06-04 | Mabylon Ag | Multispecific anti-allergen antibodies and uses thereof |
| WO2025222170A1 (en) * | 2024-04-19 | 2025-10-23 | Zb17 Llc | Methods of treatment |
| WO2025222168A1 (en) * | 2024-04-19 | 2025-10-23 | Zb17 Llc | Methods of treatment |
| WO2025222167A1 (en) * | 2024-04-19 | 2025-10-23 | Zb17 Llc | Methods of treatment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
| AR035119A1 (es) * | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
| KR20140053410A (ko) * | 2005-08-19 | 2014-05-07 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| PL1963368T6 (pl) * | 2005-12-13 | 2021-02-08 | Eli Lilly And Company | Przeciwciała anty-IL-17 |
| WO2011141823A2 (en) * | 2010-05-14 | 2011-11-17 | Orega Biotech | Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists |
| AR090626A1 (es) * | 2012-04-20 | 2014-11-26 | Lilly Co Eli | Anticuerpos anti-baff-anti-il-17 biespecificos |
-
2013
- 2013-04-08 AR ARP130101134A patent/AR090626A1/es active IP Right Grant
- 2013-04-12 TW TW102113167A patent/TWI585103B/zh not_active IP Right Cessation
- 2013-04-16 MX MX2014012692A patent/MX367460B/es active IP Right Grant
- 2013-04-16 BR BR112014025649A patent/BR112014025649A2/pt not_active Application Discontinuation
- 2013-04-16 SG SG11201406726PA patent/SG11201406726PA/en unknown
- 2013-04-16 ES ES17153380T patent/ES2789474T3/es active Active
- 2013-04-16 IN IN1876MUN2014 patent/IN2014MN01876A/en unknown
- 2013-04-16 AP AP2014008002A patent/AP2014008002A0/xx unknown
- 2013-04-16 HR HRP20170468TT patent/HRP20170468T1/hr unknown
- 2013-04-16 EP EP17153380.5A patent/EP3192809B1/en active Active
- 2013-04-16 CN CN201380020761.7A patent/CN104220455B/zh active Active
- 2013-04-16 US US13/863,544 patent/US9359448B2/en active Active
- 2013-04-16 DK DK13726321.6T patent/DK2838920T3/en active
- 2013-04-16 LT LTEP13726321.6T patent/LT2838920T/lt unknown
- 2013-04-16 RS RS20170160A patent/RS55729B1/sr unknown
- 2013-04-16 PT PT137263216T patent/PT2838920T/pt unknown
- 2013-04-16 EA EA201491622A patent/EA029185B1/ru not_active IP Right Cessation
- 2013-04-16 AU AU2013249546A patent/AU2013249546B2/en not_active Ceased
- 2013-04-16 SI SI201330522A patent/SI2838920T1/sl unknown
- 2013-04-16 PE PE2014001619A patent/PE20142147A1/es active IP Right Grant
- 2013-04-16 HU HUE13726321A patent/HUE032153T2/en unknown
- 2013-04-16 PL PL13726321T patent/PL2838920T3/pl unknown
- 2013-04-16 EP EP13726321.6A patent/EP2838920B1/en active Active
- 2013-04-16 JP JP2015507095A patent/JP6216772B2/ja active Active
- 2013-04-16 MY MYPI2014703075A patent/MY173282A/en unknown
- 2013-04-16 WO PCT/US2013/036677 patent/WO2013158577A1/en not_active Ceased
- 2013-04-16 NZ NZ630865A patent/NZ630865A/en not_active IP Right Cessation
- 2013-04-16 ME MEP-2017-41A patent/ME02596B/me unknown
- 2013-04-16 KR KR1020147028867A patent/KR101673735B1/ko not_active Expired - Fee Related
- 2013-04-16 CA CA2869148A patent/CA2869148C/en active Active
- 2013-04-16 ES ES13726321.6T patent/ES2621917T3/es active Active
-
2014
- 2014-09-30 CL CL2014002616A patent/CL2014002616A1/es unknown
- 2014-10-02 IL IL234965A patent/IL234965B/en active IP Right Grant
- 2014-10-06 CR CR20140466A patent/CR20140466A/es unknown
- 2014-10-07 ZA ZA2014/07272A patent/ZA201407272B/en unknown
- 2014-10-15 GT GT201400217A patent/GT201400217A/es unknown
- 2014-10-16 DO DO2014000234A patent/DOP2014000234A/es unknown
- 2014-10-17 EC ECIEPI201423405A patent/ECSP14023405A/es unknown
- 2014-10-17 PH PH12014502333A patent/PH12014502333B1/en unknown
- 2014-10-20 CO CO14231938A patent/CO7160039A2/es unknown
-
2016
- 2016-05-18 US US15/157,782 patent/US9708402B2/en active Active
-
2017
- 2017-03-27 CY CY20171100380T patent/CY1118824T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2023013I1 (el) | Συζευγματα αντισωματων πυρρολοβενζοδιαζεπινης | |
| CY2022002I2 (el) | Αντισωματα που προσδενονται στην il-17a και στην il-17f | |
| IL272831A (en) | Meditopes and meditope-binding antibodies and uses thereof | |
| CY1123079T1 (el) | Τροποποιημενα πολυπεπτιδια γiα ικριωματα διειδικων αντισωματων | |
| IL259979A (en) | Antibodies that bind to ox40 and their uses | |
| EA201400579A1 (ru) | Антитела к il-36r | |
| EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
| EA201890548A1 (ru) | Антитела к il-23 | |
| ZA201500457B (en) | Anti-kit antibodies and uses thereof | |
| SI2852615T1 (sl) | IL-17A/F IL-23 bispecifična protitelesa in njihova uporaba | |
| EA201401204A1 (ru) | Антитела к il-23p19 | |
| SG10201604699VA (en) | Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use | |
| MX2015011075A (es) | Peptidos terapeuticos. | |
| HUE042898T2 (hu) | Antitestek, amelyek kötnek CSF1R-t | |
| DK3156416T3 (da) | Sekvenssymmetriske modificerede bispecifikke igg4-antistoffer | |
| PL2847225T3 (pl) | Przeciwciała przeciwko klaudynie 18.2 przydatne w diagnostyce nowotworów | |
| IL234965B (en) | Anti-baff and anti-il-17 bispecific antibodies | |
| EP2814846A4 (en) | BIS-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND THERAPEUTIC USES THEREOF | |
| PL3071593T3 (pl) | Konstruowane ludzkie receptory komórek T o wysokim powinowactwie | |
| EP2870397A4 (en) | UNFINED FLEXIBLE TUBE | |
| PT2922872T (pt) | Anticorpos biespecíficos de egfr/c-met | |
| HRP20181874T1 (hr) | Anti-cxcr3 protutijela | |
| SI3030519T1 (sl) | Triciklične benzoksaborolne spojine in njihove uporabe | |
| EP2999959A4 (en) | TWO-PIECE ARRANGEMENT | |
| EP2695897A4 (en) | NEW ANTI-RECEPTOR ANTIBODY OF IL-23 HUMAN |